Expertise to support high quality immunohistochemistry and immunofluorescence antibody optimization to generate reliable quantitative pathology data for preclinical research and clinical trials.
Expert study planning and antibody selection support.
Extensive in-house mouse, rat, and human control tissue bank.
Instant access to whole slide images from optimization.
Optimization report with detailed staining protocol.
Reveal has successfully optimized over 300+ commercially-available and novel antibodies over the last year. Our experts review relevant literature to determine the best tissue controls and conditions to start your optimization.
Single-Tissue: Optimization of a commercially-available antibody on one known-positive control tissue
Two-Tissue: Optimization of a commercially-available antibody on two tissue samples: a projected or known positive control tissue and a projected low/non-expressing tissue sample. This is primarily relevant to treatment-dependent assays.
Optimize multiple antibody clones that target one marker. A Reveal scientist will determine which antibodies are the most suitable candidates for staining on your tissue.
Assess antibody specificity to the marker of interest using positive and negative cell pellet samples.
Antibody optimization to obtain optimal staining conditions that are specific to provided xenograft tumor tissue samples.
Antibody optimization using a custom/novel antibody that has few to no supporting references or literature for IHC/IF applications.
Optimization Study Planning
Reveal’s team of scientists are experienced with antibody optimization for hundreds of unique markers on different tissue types and species. We support you at every step to understand your study goals, procure antibodies, select appropriate control tissues, and develop an optimized IHC/IF protocol designed based on your needs.
Review Optimization Outcomes
Whole slide images for tested conditions are made immediately available to you through our imageDx™ cloud-based pathology platform. Our scientists collaborate with you in real time to review your optimization results.
Detailed Optimization Report
Optimization results are summarized in a detailed report which includes information about control tissues & provided samples, antibodies & reagents used, staining protocol, representative snapshots, along with our scientists’ recommendations for optimized conditions and follow-up steps.
As part of CellCarta’s scientific network, Reveal connects you with CAP/CLIA accredited labs for a continuous workflow from early drug discovery to clinical validation for your antibody or panel of interest.
Start your antibody optimization project with Reveal and we’ll transfer the assay to one of your clinical labs when you’re ready.
Boehme, SA, Franz-Bacon, K, Ludka, J, DiTirro, DN, Ly, TW, & Bacon, KB (2016) MAP3K19 Is Overexpressed in COPD and Is a Central Mediator of Cigarette Smoke-Induced Pulmonary Inflammation and Lower Airway Destruction. PLoS ONE 11(12): e0167169.
Kianna Y. Elahi-Gedwillo, KY, Marjorie Carlson, M, Jon Zettervall, J, & Provenzano, PP (2019) Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma. Cancer Research 79(2), 372-386.
Luchtel, RA, Bhagat, T, Pradhan, K, Jacobs, WR, Levine, M, Verma, A, & Shenoy, N (2020) High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model. Proceedings of the National Academy of Sciences of the United States of America, Jan, 7, 2020; DOI: 10.1073/pnas.1908158117.
Marvin K, Schwartz I, Utz E, Wilson J, Johnson C, Gaudreau P. Effects of Fractional CO2 Laser Treatment on Subglottic Scar in a Rabbit Model. Otolaryngology–Head and Neck Surgery. 2020 Dec 8:0194599820978256.
Nag, D, Farr, D, Raychaudhuri, S, & Withey, JH. (2022). An adult zebrafish model for adherent-invasive Escherichia coli indicates protection from AIEC infection by probiotic E. coli Nissle. iScience, 25(7), 104572.
Proia, DA, Smith, DL, Zhang, J, Jimenez, J-P, Sang, J, Ogawa, LS, Sequeira, M, Acquaviva, J, He, S, Zhang, C, Khazak, V, Astsaturov, I, Inoue, T, Tatsuta, N, Osman, S, Bates, RC, Chimmanamada, C, & Ying, W (2015) HSP90 Inhibitor–SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors. Molecular Cancer Therapeutics 14(11), 2422-2432.
Shields, BD, Koss, B, Taylor, EM, Storey, AJ, West, KL, Byrum, SD, Mackintosh, SG, Edmondson, R, Mahmoud, F, Shalin, SC, & Tackett, AJ (2019) Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. Cancer Research 79(6), 1113-1123.
Verco, J, Johnston, W, Frost, M, Baltezor, M, Kuehl, PJ, Lopez, A, Gigliotti, A, Belinsky, SA, Wolff, R, & diZerega, G (2019) Inhaled Submicron Particle Paclitaxel (NanoPac) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer. Journal of Aerosol Medicine and Pulmonary Drug Delivery 32(5), 266-277.
Wallace EM, Rizzi, JP, Han, G, Wehn, PM, Cao, Z Du, X, Cheng, T, Czerwinski, RM, Dixon, DD, Goggin, BS, Grina, JA, Halfmann, MM, Maddie, MA, Olive, SR, Schlachter, ST, Tan, H, Wang, B, Wang, K, Xie, S, Xu, R, Yang, H & Josey, JA (2016) A Small-Molecule Antagonist of HIF2a Is Efficacious in Preclinical Models of Renal Cell Carcinoma. Cancer Research 76(18), 5491-5500.
Wang H, Hoffman C, Yang X, Clapp B, Pascual DW (2020) Targeting resident memory T cell immunity culminates in pulmonary and systemic protection against Brucella infection. PLoS pathogens, 16(1):e1008176.